Prostaglandin D2 Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone–Mineralocorticoid Receptor Pathway in the Heart
Cells · 2025
DOI: 10.3390/cells14191485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ankita Garg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, 30625 Hannover, Germany. Hauptthemen laut MEDLINE: Intramolecular Oxidoreductases, Lipocalins, Signal Transduction, Receptors, Mineralocorticoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DFG, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
A deregulated aldosterone (Aldo)–mineralocorticoid receptor (MR) pathway is linked to cardiovascular disease (CVD), including hypertension and heart failure. Despite the association of elevated plasma Aldo levels with cardiac stress, inflammation, myocardial fibrosis, and cardiac remodeling, the underlying mechanisms remain elusive.
Methods
To study the impact of Aldo–MR pathway overactivation on cardiac health, a novel mouse model with AAV9-mediated MR overexpression and Aldo administration via subcutaneous osmotic pumps was generated. Echocardiographic analyses, transcriptome sequencing, and loss-of-function experiments of an identified lead candidate gene were performed. Additionally, cardiac tissue samples from human patients with end-stage heart failure were analyzed in the study.
Results
Mice with an overactivated Aldo–MR pathway exhibited increased neutrophil gelatinase-associated lipocalin (NGAL) expression, cardiac dysfunction, hypertrophy, and fibrosis. Transcriptomics identified prostaglandin D2 synthase (Ptgds) as a novel downstream effector of the cardiac Aldo–MR pathway. SiRNA-mediated inhibition of Ptgds in primary cardiomyocytes reduced NGAL levels and the hypertrophic impact of Aldo, suggesting a role in mediating Aldo-induced cardiac pathologies. Elevated expression of PTGDS was observed in hiPSC-CMs treated with the pro-hypertrophic cytokine leukemia inhibitory factor (LIF) and in end-stage heart failure patients, ascertaining its importance in cardiac disease settings.
Conclusions
PTGDS is a newly identified mediator of Aldo–MR-induced cardiac remodeling and may represent a potential therapeutic target for CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, 30625 Hannover, Germany.
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), 30625 Hannover, Germany.
- Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD), 30625 Hannover, Germany.
ORCID-Profile: Carla Nunes Borisch, Julia Leonardy, Christian Bär, Thomas Thum
Förderung
- DFG
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Garg, A., Juchem, M., Biss, S., Borisch, C. N., Leonardy, J., Bär, C., Gupta, S. K., & Thum, T. (2025). Prostaglandin D2 Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone–Mineralocorticoid Receptor Pathway in the Heart. Cells. https://doi.org/10.3390/cells14191485
Vancouver
Garg A, Juchem M, Biss S, Borisch CN, Leonardy J, Bär C, et al. Prostaglandin D2 Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone–Mineralocorticoid Receptor Pathway in the Heart. Cells. 2025. doi:10.3390/cells14191485
BibTeX
@article{Garg2025,
author = {Garg, Ankita and Juchem, Malte and Biss, Sinje and Borisch, Carla Nunes and Leonardy, Julia and Bär, Christian and Gupta, Shashi Kumar and Thum, Thomas},
title = {Prostaglandin D2 Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone–Mineralocorticoid Receptor Pathway in the Heart},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14191485}
}
EUVIMED